Verbascoside alleviates pneumococcal pneumonia by reducing pneumolysin oligomerss

Molecular Pharmacology

Volumn 89, Issue 3, 2016, Pages 376-387

  Zhao, Xiaoran ^a   Li, Hongen ^a   Wang, Jianfeng ^a   Guo, Yan ^a   Liu, Bowen ^a   Deng, Xuming ^a   Niu, Xiaodi ^a  

^a JILIN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACTEOSIDE; OLIGOMER; PNEUMOLYSIN; ANTIINFECTIVE AGENT; BACTERIAL PROTEIN; GLUCOSIDE; PHENOL DERIVATIVE; PLY PROTEIN, STREPTOCOCCUS PNEUMONIAE; STREPTOLYSIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DAMAGE; CONTROLLED STUDY; HEMOLYSIS; HUMAN; HUMAN CELL; LUNG ALVEOLUS EPITHELIUM CELL; LUNG INJURY; MALE; MOLECULAR DYNAMICS; MORTALITY; MUTATIONAL ANALYSIS; NONHUMAN; OLIGOMERIZATION; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIA; ANIMAL; ANTAGONISTS AND INHIBITORS; BINDING SITE; C57BL MOUSE; DRUG EFFECTS; FEMALE; METABOLISM; MOUSE; PHYSIOLOGY; PNEUMONIA, PNEUMOCOCCAL; PROTEIN SECONDARY STRUCTURE; PROTEIN TERTIARY STRUCTURE; SHEEP; STREPTOCOCCUS PNEUMONIAE;

ANIMALS; ANTI-INFECTIVE AGENTS; BACTERIAL PROTEINS; BINDING SITES; FEMALE; GLUCOSIDES; HUMANS; MICE; MICE, INBRED C57BL; PHENOLS; PNEUMONIA, PNEUMOCOCCAL; PROTEIN STRUCTURE, SECONDARY; PROTEIN STRUCTURE, TERTIARY; SHEEP; STREPTOCOCCUS PNEUMONIAE; STREPTOLYSINS;

EID: 84962261894     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.115.100610     Document Type: Article

References (51)

1. Balachandran P, Hollingshead SK, Paton JC, and Briles DE (2001) The autolytic enzyme LytA of Streptococcus pneumoniae is not responsible for releasing pneumolysin. J Bacteriol 183:3108-3116.
2. Barrett CP and Noble ME (2005) Molecular motions of human cyclin-dependent kinase 2. J Biol Chem 280:13993-14005.
3. Berry AM, Yother J, Briles DE, Hansman D, and Paton JC (1989) Reduced virulence of a defined pneumolysin-negative mutant of Streptococcus pneumoniae. Infect Immun 57:2037-2042.
4. Black RE, Cousens S, Johnson HL, Lawn JE, Rudan I, Bassani DG, Jha P, Campbell H, Walker CF, and Cibulskis R et al.; Child Health Epidemiology Reference Group of WHO and UNICEF (2010) Global, regional, and national causes of child mortality in 2008: a systematic analysis. Lancet 375:1969-1987.
5. Boulnois GJ, Paton JC, Mitchell TJ, and Andrew PW (1991) Structure and function of pneumolysin, the multifunctional, thiol-activated toxin of Streptococcus pneumoniae. Mol Microbiol 5:2611-2616.
6. Braun JS, Sublett JE, Freyer D, Mitchell TJ, Cleveland JL, Tuomanen EI, and Weber JR (2002) Pneumococcal pneumolysin and H(2)O(2) mediate brain cell apoptosis during meningitis. J Clin Invest 109:19-27.
7. Campbell GD, Jr and Silberman R (1998) Drug-resistant Streptococcus pneumoniae. Clin Infect Dis 26:1188-1195.
8. Chiou WF, Lin LC, and Chen CF (2004) Acteoside protects endothelial cells against free radical-induced oxidative stress. J Pharm Pharmacol 56:743-748.
9. Dessing MC, Florquin S, Paton JC, and van der Poll T (2008) Toll-like receptor 2 contributes to antibacterial defence against pneumolysin-deficient pneumococci. Cell Microbiol 10:237-246.
10. Dessing MC, Knapp S, Florquin S, de Vos AF, and van der Poll T (2007) CD14 facilitates invasive respiratory tract infection by Streptococcus pneumoniae. Am J Respir Crit Care Med 175:604-611.
11. Dong J, Qiu J, Zhang Y, Lu C, Dai X, Wang J, Li H, Wang X, Tan W, and Luo M et al. (2013) Oroxylin A inhibits hemolysis via hindering the self-assembly of a-hemolysin heptameric transmembrane pore. PLOS Comput Biol 9:e1002869.
12. Gilbert RJ, Jiménez JL, Chen S, Tickle IJ, Rossjohn J, Parker M, Andrew PW, and Saibil HR (1999) Two structural transitions in membrane pore formation by pneumolysin, the pore-forming toxin of Streptococcus pneumoniae. Cell 97: 647-655.
13. Gilbert RJ, Rossjohn J, Parker MW, Tweten RK, Morgan PJ, Mitchell TJ, Errington N, Rowe AJ, Andrew PW, and Byron O (1998) Self-interaction of pneumolysin, the pore-forming protein toxin of Streptococcus pneumoniae. J Mol Biol 284: 1223-1237.
14. Hess B, Kutzner C, van der Spoel D, and Lindahl E (2008) GROMACS 4: Algorithms for highly efficient, load-balanced, and scalable molecular simulation. J Chem Theory Comput 4:435-447.
15. Hidalgo M, Castaneda E, and Arias CA (2003) Tolerance to vancomycin in a multiresistant, Colombian isolate of Streptococcus pneumoniae. J Antimicrob Chemother 52:300-302.
16. Hu R, Barbault F, Delamar M, and Zhang R (2009) Receptor- and ligand-based 3D-QSAR study for a series of non-nucleoside HIV-1 reverse transcriptase inhibitors. Bioorg Med Chem 17:2400-2409.
17. Jedrzejas MJ (2001) Pneumococcal virulence factors: structure and function. Microbiol Mol Biol Rev 65:187-207 first page, table of contents.
18. Jogalekar AS, Reiling S, and Vaz RJ (2010) Identification of optimum computational protocols for modeling the aryl hydrocarbon receptor (AHR) and its interaction with ligands. Bioorg Med Chem Lett 20:6616-6619.
19. Jorgensen WL, Chandrasekhar J, Madura JD, Impey RW, and Klein ML (1983) Comparison Of Simple Potential Functions for Simulating Liquid Water. J Chem Phys 79:926-935.
20. Laskowski RA, Moss DS, and Thornton JM (1993) Main-chain bond lengths and bond angles in protein structures. J Mol Biol 231:1049-1067.
21. Li Y, Gan L, Li GQ, Deng L, Zhang X, and Deng Y (2014) Pharmacokinetics of plantamajoside and acteoside from Plantago asiatica in rats by liquid chromatography-mass spectrometry. J Pharm Biomed Anal 89:251-256.
22. Liu M, Su JG, Kong R, Sun TG, Tan JJ, Chen WZ, and Wang CX (2008) Molecular dynamics simulations of the bacterial periplasmic heme binding proteins ShuT and PhuT. Biophys Chem 138:42-49.
23. Morris GM, Goodsell DS, Huey R, and Olson AJ (1996) Distributed automated docking of flexible ligands to proteins: parallel applications of AutoDock 2.4. J Comput Aided Mol Des 10:293-304.
24. Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, and Olson AJ (2009) AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J Comput Chem 30:2785-2791.
25. Musher DM, Phan HM, and Baughn RE (2001) Protection against bacteremic pneumococcal infection by antibody to pneumolysin. J Infect Dis 183:827-830.
26. Niu X, Qiu J, Wang X, Gao X, Dong J, Wang J, Li H, Zhang Y, Dai X, and Lu C et al. (2013) Molecular insight into the inhibition mechanism of cyrtominetin to a-hemolysin by molecular dynamics simulation. Eur J Med Chem 62:320-328.
27. Novak R, Henriques B, Charpentier E, Normark S, and Tuomanen E (1999) Emergence of vancomycin tolerance in Streptococcus pneumoniae. Nature 399: 590-593.
28. Palmer M (2001) The family of thiol-activated, cholesterol-binding cytolysins. Toxicon 39: 1681-1689.
29. Paton JC, Andrew PW, Boulnois GJ, and Mitchell TJ (1993) Molecular analysis of the pathogenicity of Streptococcus pneumoniae: the role of pneumococcal proteins. Annu Rev Microbiol 47:89-115.
30. Paton JC, Lock RA, and Hansman DJ (1983) Effect of immunization with pneumolysin on survival time of mice challenged with Streptococcus pneumoniae. Infect Immun 40:548-552.
31. Paton JC, Rowan-Kelly B, and Ferrante A (1984) Activation of human complement by the pneumococcal toxin pneumolysin. Infect Immun 43:1085-1087.
32. Price KE and Camilli A (2009) Pneumolysin localizes to the cell wall of Streptococcus pneumoniae. J Bacteriol 191:2163-2168.
33. Pu X, Song Z, Li Y, Tu P, and Li H (2003) Acteoside from Cistanche salsa inhibits apoptosis by 1-methyl-4-phenylpyridinium ion in cerebellar granule neurons. Planta Med 69:65-66.
34. Qiu J, Niu X, Dong J, Wang D, Wang J, Li H, Luo M, Li S, Feng H, and Deng X (2012) Baicalin protects mice from Staphylococcus aureus pneumonia via inhibition of the cytolytic activity of a-hemolysin. J Infect Dis 206:292-301.
35. Qiu J, Wang D, Zhang Y, Dong J, Wang J, and Niu X (2013) Molecular modeling reveals the novel inhibition mechanism and binding mode of three natural compounds to staphylococcal a-hemolysin. PLoS One 8:e80197.
36. Ragle BE, Karginov VA, and Bubeck Wardenburg J (2010) Prevention and treatment of Staphylococcus aureus pneumonia with a beta-cyclodextrin derivative. Antimicrob Agents Chemother 54:298-304.
37. Rasko DA and Sperandio V (2010) Anti-virulence strategies to combat bacteriamediated disease. Nat Rev Drug Discov 9:117-128.
38. Rungrotmongkol T, Nunthaboot N, Malaisree M, Kaiyawet N, Yotmanee P, Meeprasert A, and Hannongbua S (2010) Molecular insight into the specific binding of ADP-ribose to the nsP3 macro domains of chikungunya and Venezuelan equine encephalitis viruses: molecular dynamics simulations and free energy calculations. J Mol Graph Model 29:347-353.
39. Ryckaert JP, Ciccotti G, and Berendsen HJC (1977) Numerical-integration of cartesian equations of notion if a system with constraints - molecular-dynamics of N-alkanes. J Comput Phys 23:327-341.
40. Schapoval EE, Vargas MR, Chaves CG, Bridi R, Zuanazzi JA, and Henriques AT (1998) Antiinflammatory and antinociceptive activities of extracts and isolated compounds from Stachytarpheta cayennensis. J Ethnopharmacol 60:53-59.
41. Schmeck B, Gross R, N'Guessan PD, Hocke AC, Hammerschmidt S, Mitchell TJ, Rosseau S, Suttorp N, and Hippenstiel S (2004) Streptococcus pneumoniae-induced caspase 6-dependent apoptosis in lung epithelium. Infect Immun 72:4940-4947.
42. Stansfield SK (1987) Acute respiratory infections in the developing world: strategies for prevention, treatment and control. Pediatr Infect Dis J 6:622-629.
43. Swanson JMJ, Henchman RH, and McCammon JA (2004) Revisiting free energy calculations: a theoretical connection to MM/PBSA and direct calculation of the association free energy. Biophys J 86:67-74.
44. Thummeepak R, Leerach N, Kunthalert D, Tangchaisuriya U, Thanwisai A, and Sitthisak S (2015) High prevalence of multi-drug resistant Streptococcus pneumoniae among healthy children in Thailand. J Infect Public Health 8:274-281.
45. Vorontsov II and Miyashita O (2011) Crystal molecular dynamics simulations to speed up MM/PB(GB)SA evaluation of binding free energies of di-mannose deoxy analogs with P51G-m4-Cyanovirin-N. J Comput Chem 32:1043-1053.
46. Wang J, Qiu J, Tan W, Zhang Y, Wang H, Zhou X, Liu S, Feng H, Li W, and Niu X et al. (2015) Fisetin inhibits Listeria monocytogenes virulence by interfering with the oligomerization of listeriolysin O. J Infect Dis 211:1376-1387.
47. Wang J, Wang W, Kollman PA, and Case DA (2006) Automatic atom type and bond type perception in molecular mechanical calculations. J Mol Graph Model 25: 247-260.
48. Werner G, Strommenger B, and Witte W (2008) Acquired vancomycin resistance in clinically relevant pathogens. Future Microbiol 3:547-562.
49. Wu K, Zhang X, Shi J, Li N, Li D, Luo M, Cao J, Yin N, Wang H, and Xu W et al. (2010) Immunization with a combination of three pneumococcal proteins confers additive and broad protection against Streptococcus pneumoniae Infections in Mice. Infect Immun 78:1276-1283.
50. Xiong Q, Hase K, Tezuka Y, Tani T, Namba T, and Kadota S (1998) Hepatoprotective activity of phenylethanoids from Cistanche deserticola. Planta Med 64:120-125.
51. Zhou R, Berne BJ, and Germain R (2001) The free energy landscape for beta hairpin folding in explicit water. Proc Natl Acad Sci USA 98:14931-14936.